- Home
- LUNG vs ABEO Comparison
LUNG vs ABEO Comparison
Compare LUNG & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUNG
- ABEO
- Stock Information
- Founded
- LUNG 1995
- ABEO N/A
- Country
- LUNG United States
- ABEO United States
- Employees
- LUNG N/A
- ABEO N/A
- Industry
- LUNG Industrial Specialties
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- LUNG Health Care
- ABEO Health Care
- Exchange
- LUNG Nasdaq
- ABEO Nasdaq
- Market Cap
- LUNG 248.0M
- ABEO 277.6M
- IPO Year
- LUNG 2020
- ABEO 1980
- Fundamental
- Price
- LUNG $6.67
- ABEO $6.41
- Analyst Decision
- LUNG Strong Buy
- ABEO Strong Buy
- Analyst Count
- LUNG 7
- ABEO 3
- Target Price
- LUNG $13.71
- ABEO $18.00
- AVG Volume (30 Days)
- LUNG 213.2K
- ABEO 290.2K
- Earning Date
- LUNG 10-28-2024
- ABEO 11-11-2024
- Dividend Yield
- LUNG N/A
- ABEO N/A
- EPS Growth
- LUNG N/A
- ABEO N/A
- EPS
- LUNG N/A
- ABEO N/A
- Revenue
- LUNG $76,583,000.00
- ABEO N/A
- Revenue This Year
- LUNG $22.73
- ABEO N/A
- Revenue Next Year
- LUNG $19.02
- ABEO $7,097.06
- P/E Ratio
- LUNG N/A
- ABEO N/A
- Revenue Growth
- LUNG 26.26
- ABEO 147.52
- 52 Week Low
- LUNG $5.46
- ABEO $3.05
- 52 Week High
- LUNG $14.84
- ABEO $9.01
- Technical
- Relative Strength Index (RSI)
- LUNG 37.51
- ABEO 61.15
- Support Level
- LUNG $6.39
- ABEO $6.39
- Resistance Level
- LUNG $7.47
- ABEO $6.74
- Average True Range (ATR)
- LUNG 0.36
- ABEO 0.31
- MACD
- LUNG -0.20
- ABEO 0.02
- Stochastic Oscillator
- LUNG 12.93
- ABEO 68.57
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.